OR WAIT null SECS
Industry Standard Research (ISR) today announced the availability of a new report titled “Improving Patient Recruitment in Biosimilar Trials,” which examines patient and site recruitment in Biosimilar clinical trials.
“Teva’s use of a Biologics License Application (BLA) for their regulatory submission and the FDA’s subsequent Biosimilar approval for two Amgen products is further evidence this industry is rapidly evolving,” explained Andrew Schafer, President of ISR. “ISR’s newest Biosimilar report provides a complete and quantitative assessment of the current state of recruitment in Biosimilar trials and will enable pharma, biotech, and their service providers to improve targeting and develop messaging that resonates with their audiences.”
The report compiles data from 103 on-site patient recruitment professionals and examines the current level of understanding they and patients have of Biosimilars, factors that drive and inhibit enrollment in Biosimilar trials, as well as recommendations to optimize recruitment efforts and increase the likelihood of participation in Biosimilar clinical trials.
ISR’s report uncovered a sizable discrepancy between what sites understand about Biosimilars and their willingness to participate as a clinical trial site – an issue that ISR says can be fixed through education.
“While only 50% of respondents were familiar with Biosimilars, a majority of respondents (61%) are interested in being an investigative site for a Biosimilar study, and 72% of research sites indicated that they would be excited or very excited if a Biosimilar protocol came across their desk,” Schafer explained.
ISR’s report also makes recommendations on the patient-centric benefits pharma and biotech should communicate to both patients and sites to increase the likelihood of participation. This report is the fifth report in ISR’s Biosimilar Knowledge Center, having just recently released two report primers: “Biosimilars in the US Oncology Market” and “US Payers and Biosimilar Formulary Placement.”